Fresh, sourced stories worth posting about for biotech & pharma professionals — updated every few hours, with the receipts attached. Not generated guesses.
Your desk is ready
Free to start · no card required · your pick is waiting on the other side.
Niche's weekly rollup — one email, no spam.
The stories refresh every few hours from live news and primary sources. Each carries the publisher and the date it was published — so you can see exactly how current it is.
Real reporting and primary filings — every story links its sources. Nothing here is a generated guess; the angle is identified and the receipts are attached.
Yes. These are starting points for your own posts. Draft one and Niche writes it in your voice, platform-native, ready to publish.
Merck Sharp & Dohme shows broad pipeline activity across multiple indications, including a phase 3 pulmonary arterial hypertension study of sotatercept, a phase 2 B-cell malignancy program for zilovertamab vedotin, a phase 3 diffuse large B-cell lymphoma trial, a phase 1/2 small cell lung cancer combination study, and a phase 2 ulcerative colitis trial.
Draft a post from this →Pfizer has a cluster of ongoing and upcoming studies spanning obesity, eczema, healthy-volunteer pharmacokinetics, and COVID-19-related drug development, including completed ibuzatrelvir tablet uptake work, a food-effect study for prifetrastat, a phase 1 obesity dose/tolerability study, a phase 1 healthy-volunteer study of PF-07799544, and a phase 2 eczema trial of PF-08049820.
Draft a post from this →Several non-Merck and non-Pfizer trials were newly surfaced, including a phase 4 tirzepatide study for idiopathic intracranial hypertension, a phase 2 avelumab endometrial cancer program, and a phase 3 sotatercept pulmonary arterial hypertension trial sponsored by Merck, reflecting continued development in respiratory, oncology, and metabolic-adjacent indications.
Draft a post from this →The week brought both forward movement and a setback in vaccine and infectious-disease R&D, with BioNTech starting a phase 4 COVID-19 vaccine study and NIAID’s malaria vaccine study in pregnant women in Mali being suspended.
Draft a post from this →Eli Lilly is appearing in both commercial and pipeline news, with a report on strong Q1 2026 earnings, a piece on the Kisunla Alzheimer’s launch, and a phase 3 lepodisiran trial aimed at reducing coronary plaque in high-risk adults with elevated Lp(a).
Draft a post from this →